{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:21:19Z","timestamp":1790673679728,"version":"4.1.0"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"am","delay-in-days":311,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejca.2022.11.028","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:54:00Z","timestamp":1670547240000},"page":"3-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency"],"prefix":"10.1016","volume":"181","author":[{"given":"Marie-Christine","family":"Etienne-Grimaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8486-3596","authenticated-orcid":false,"given":"Nicolas","family":"Pallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Boige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1733-3410","authenticated-orcid":false,"given":"Joseph","family":"Ciccolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9626-3571","authenticated-orcid":false,"given":"Laurent","family":"Chouchana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Barin-Le Guellec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Zaanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Narjoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-412X","authenticated-orcid":false,"given":"Fabienne","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.11.028_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2019.09.028","article-title":"Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: a real-life evaluation in France","volume":"124","author":"Barin-Le Guellec","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","article-title":"Clinical pharmacology of 5-fluorouracil","volume":"16","author":"Diasio","year":"1989","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejca.2022.11.028_bib3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1517\/14656566.3.6.733","article-title":"Capecitabine: fulfilling the promise of oral chemotherapy","volume":"3","author":"Marshall","year":"2002","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.ejca.2022.11.028_bib4","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/01.ftd.0000245771.82720.c7","article-title":"A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy","volume":"28","author":"Ciccolini","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ejca.2022.11.028_bib5","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/onco.13967","article-title":"Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis","volume":"26","author":"Sharma","year":"2021","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2022.11.028_bib6","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(14)70227-X","article-title":"Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial","volume":"15","author":"Taieb","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.11.028_bib7","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.11.028_bib8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2006.08.1075","article-title":"Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients","volume":"25","author":"Schmoll","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.11.028_bib9","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ijc.29025","article-title":"Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity","volume":"136","author":"Froehlich","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical pharmacogenetics implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejca.2022.11.028_bib11","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","article-title":"Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors","volume":"16","author":"L\u00e9vy","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.11.028_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1524-4733.2002.51083.x","article-title":"The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer","volume":"5","author":"Delea","year":"2002","journal-title":"Value Health"},{"key":"10.1016\/j.ejca.2022.11.028_bib13","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","article-title":"Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil","volume":"40","author":"van Kuilenburg","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib14","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s002800051022","article-title":"Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans","volume":"45","author":"Guimbaud","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2022.11.028_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.lungcan.2011.12.018","article-title":"Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues","volume":"77","author":"Hirota","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib17","first-page":"33","article-title":"Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues","volume":"17","author":"Mori","year":"2000","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejca.2022.11.028_bib18","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.11.028_bib19","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"Etienne","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.11.028_bib20","first-page":"507","article-title":"Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver","volume":"2","author":"Chazal","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.11.028_bib21","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/cpt.1124","article-title":"Therapeutic drug monitoring in oncology: International association of therapeutic drug monitoring and clinical toxicology recommendations for 5-fluorouracil therapy","volume":"105","author":"Beumer","year":"2019","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.ejca.2022.11.028_bib22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00280-020-04208-8","article-title":"Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients","volume":"87","author":"Lunar","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2022.11.028_bib23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM198507253130407","article-title":"Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity","volume":"313","author":"Tuchman","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.11.028_bib24","first-page":"4363","article-title":"Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity","volume":"9","author":"van Kuilenburg","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.11.028_bib25","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1535-7163.MCT-06-0327","article-title":"Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance","volume":"5","author":"Morel","year":"2006","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.ejca.2022.11.028_bib26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","article-title":"5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency","volume":"249","author":"Boisdron-Celle","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ejca.2022.11.028_bib27","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.tips.2007.09.009","article-title":"Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?","volume":"28","author":"Mercier","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.ejca.2022.11.028_bib28","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1158\/1078-0432.CCR-10-2209","article-title":"Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer","volume":"17","author":"Deenen","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.11.028_bib29","first-page":"224","article-title":"Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?","volume":"9","author":"Ciccolini","year":"2010","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib30","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2013.51.1857","article-title":"Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis","volume":"32","author":"Rosmarin","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.11.028_bib31","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/bjc.2013.262","article-title":"Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity","volume":"108","author":"Loganayagam","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib32","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1006\/geno.1998.5379","article-title":"Characterization of the human dihydropyrimidine dehydrogenase gene","volume":"51","author":"Wei","year":"1998","journal-title":"Genomics"},{"key":"10.1016\/j.ejca.2022.11.028_bib33","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/ijc.29654","article-title":"Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines","volume":"137","author":"Toffoli","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib34","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/0008-5472.CAN-13-2482","article-title":"Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity","volume":"74","author":"Offer","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2022.11.028_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00008711","article-title":"Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency","volume":"104","author":"Van Kuilenburg","year":"1999","journal-title":"Hum Genet"},{"key":"10.1016\/j.ejca.2022.11.028_bib36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00280-006-0392-5","article-title":"DPYD\u22172A mutation: the most common mutation associated with DPD deficiency","volume":"60","author":"Saif","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2022.11.028_bib37","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1200\/JCO.2009.21.7943","article-title":"Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741","volume":"28","author":"McLeod","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.11.028_bib38","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1124\/dmd.118.081737","article-title":"Functional characterization of 21 allelic variants of dihydropyrimidine dehydrogenase identified in 1070 Japanese individuals","volume":"46","author":"Hishinuma","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ejca.2022.11.028_bib39","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/clpt.2013.69","article-title":"A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity","volume":"94","author":"Offer","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejca.2022.11.028_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.626954","article-title":"Potential impact of DPYD variation on fluoropyrimidine drug response in sub-Saharan african populations","volume":"12","author":"da Rocha","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.ejca.2022.11.028_bib41","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/clpt.2013.172","article-title":"Clinical pharmacogenetics implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing","volume":"94","author":"Caudle","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejca.2022.11.028_bib42","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/cpt.531","article-title":"Novel deleterious dihydropyrimidine dehydrogenase variants may contribute to 5-fluorouracil sensitivity in an East african population","volume":"101","author":"Elraiyah","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejca.2022.11.028_bib43","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/BF01799841","article-title":"A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency","volume":"19","author":"Vreken","year":"1996","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ejca.2022.11.028_bib44","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1158\/0008-5472.CAN-12-3858","article-title":"Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in\u00a0vitro measurement of enzyme activity","volume":"73","author":"Offer","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2022.11.028_bib45","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00008571-199812000-00001","article-title":"Nomenclature for human DPYD alleles","volume":"8","author":"McLeod","year":"1998","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ejca.2022.11.028_bib46","first-page":"4705","article-title":"Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene","volume":"6","author":"van Kuilenburg","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.11.028_bib47","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0959-8049(97)00261-X","article-title":"Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity","volume":"33","author":"Van Kuilenburg","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib48","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/15257770802145009","article-title":"Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene","volume":"27","author":"van Kuilenburg","year":"2008","journal-title":"Nucleos Nucleot Nucleic Acids"},{"key":"10.1016\/j.ejca.2022.11.028_bib49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF03257473","article-title":"Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy","volume":"51","author":"van Kuilenburg","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejca.2022.11.028_bib50","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00008571-200004000-00002","article-title":"Known variant DPYD alleles do not explain DPD deficiency in cancer patients","volume":"10","author":"Collie-Duguid","year":"2000","journal-title":"Pharmacogenetic"},{"key":"10.1016\/j.ejca.2022.11.028_bib51","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1042\/bj3640157","article-title":"Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure","volume":"364","author":"van Kuilenburg","year":"2002","journal-title":"Biochem J"},{"key":"10.1016\/j.ejca.2022.11.028_bib52","first-page":"768","article-title":"Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype","volume":"8","author":"Johnson","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.11.028_bib53","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1158\/1078-0432.CCR-04-1784","article-title":"Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals","volume":"11","author":"Seck","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.11.028_bib54","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00439-010-0879-3","article-title":"Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity","volume":"128","author":"van Kuilenburg","year":"2010","journal-title":"Hum Genet"},{"key":"10.1016\/j.ejca.2022.11.028_bib55","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/cpt.685","article-title":"Quantitative contribution of rs75017182 to dihydropyrimidine dehydrogenase mRNA splicing and enzyme activity","volume":"102","author":"Nie","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejca.2022.11.028_bib56","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2217\/pgs.15.70","article-title":"Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score","volume":"16","author":"Henricks","year":"2015","journal-title":"Pharmacogenomic"},{"key":"10.1016\/j.ejca.2022.11.028_bib57","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","article-title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene\u2013drug interaction of DPYD and fluoropyrimidines","volume":"28","author":"Lunenburg","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ejca.2022.11.028_bib58","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/bjc.2017.94","article-title":"Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity","volume":"116","author":"Meulendijks","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175998","article-title":"New advances in DPYD genotype and risk of severe toxicity under capecitabine","volume":"12","author":"Etienne-Grimaldi","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2022.11.028_bib60","unstructured":"https:\/\/www.annalsofoncology.org\/issue\/S0923-7534(19)X9100-0 (accessed September 30, 2021)."},{"key":"10.1016\/j.ejca.2022.11.028_bib61","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.11.028_bib62","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamaoncol.2015.5392","article-title":"DPYD genotyping to predict adverse events following treatment with fluorouracil-based adjuvant chemotherapy in patients with stage III colon cancer: a secondary analysis of the PETACC-8 randomized clinical trial","volume":"2","author":"Boige","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.11.028_bib63","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1158\/1078-0432.CCR-05-2020","article-title":"The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil","volume":"12","author":"Mattison","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.11.028_bib64","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0378-4347(95)00228-B","article-title":"Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography","volume":"672","author":"Sumi","year":"1995","journal-title":"J Chromatogr B Biomed Appl"},{"key":"10.1016\/j.ejca.2022.11.028_bib65","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1570-0232(02)00009-0","article-title":"Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography-tandem mass spectrometry","volume":"769","author":"Jiang","year":"2002","journal-title":"J Chromatogr, B: Anal Technol Biomed Life Sci"},{"key":"10.1016\/j.ejca.2022.11.028_bib66","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jchromb.2005.05.044","article-title":"An accurate dihydrouracil\/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice","volume":"823","author":"Remaud","year":"2005","journal-title":"J Chromatogr, B: Anal Technol Biomed Life Sci"},{"key":"10.1016\/j.ejca.2022.11.028_bib67","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/cts.12762","article-title":"A simple and rapid UPLC-UV method for detecting DPD deficiency in patients with cancer","volume":"13","author":"Marin","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ejca.2022.11.028_bib68","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1570-0232(03)00044-8","article-title":"Rapid gas chromatographic-mass spectrometric diagnosis of dihydropyrimidine dehydrogenase deficiency and dihydropyrimidinase deficiency","volume":"792","author":"Kuhara","year":"2003","journal-title":"J Chromatogr, B: Anal Technol Biomed Life Sci"},{"key":"10.1016\/j.ejca.2022.11.028_bib69","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00280-014-2553-2","article-title":"Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy","volume":"74","author":"Carlsson","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2022.11.028_bib70","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.clinbiochem.2016.07.004","article-title":"Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies","volume":"49","author":"Galarza","year":"2016","journal-title":"Clin Biochem"},{"key":"10.1016\/j.ejca.2022.11.028_bib71","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/FTD.0000000000000615","article-title":"Determination of endogenous concentrations of uracil and dihydrouracil in dried saliva spots by LC-MS\/MS: method development, validation, and clinical application","volume":"41","author":"Antunes","year":"2019","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ejca.2022.11.028_bib72","doi-asserted-by":"crossref","first-page":"P3","DOI":"10.1158\/0008-5472.SABCS13-P3-15-04","article-title":"Abstract P3-15-04: a French prospective pilot study to identify dihydropyrimidine dehydrogenase (DPD) deficiency in breast cancer patients receiving capecitabine","volume":"73","author":"Milano","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2022.11.028_bib73","doi-asserted-by":"crossref","unstructured":"Maillard M, Launay M, Royer B, Guitton J, Gautier-Veyret E, Broutin S, et\u00a0al. Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency. Br J Clin Pharmacol n.d.;n\/a. https:\/\/doi.org\/10.1111\/bcp.15536.","DOI":"10.1111\/bcp.15536"},{"key":"10.1016\/j.ejca.2022.11.028_bib74","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0925-4439(02)00076-5","article-title":"Homeostatic control of uridine and the\u00a0role of uridine phosphorylase: a biological and clinical update","volume":"1587","author":"Pizzorno","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ejca.2022.11.028_bib75","doi-asserted-by":"crossref","unstructured":"de With M, Knikman J, de Man FM, Lunenburg CATC, Henricks LM, van Kuilenburg ABP, et\u00a0al. Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study. Clinical Pharmacology & Therapeutics n.d.;n\/a. https:\/\/doi.org\/10.1002\/cpt.2608.","DOI":"10.1002\/cpt.2608"},{"key":"10.1016\/j.ejca.2022.11.028_bib76","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1111\/bcp.13719","article-title":"Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers","volume":"84","author":"Henricks","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejca.2022.11.028_bib77","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/sj.bjp.0705651","article-title":"Circadian rhythm of dihydrouracil\/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels","volume":"141","author":"Jiang","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ejca.2022.11.028_bib78","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00280-021-04354-7","article-title":"Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results","volume":"88","author":"Gaible","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2022.11.028_bib79","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/chromsci\/bms085","article-title":"Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5,6-dihydrouracil in human plasma","volume":"50","author":"Coudor\u00e9","year":"2012","journal-title":"J Chromatogr Sci"},{"key":"10.1016\/j.ejca.2022.11.028_bib80","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.annonc.2021.02.020","article-title":"Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation","volume":"32","author":"Thomas","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.11.028_bib81","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41416-020-0962-z","article-title":"A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency","volume":"123","author":"Pallet","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib82","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2018.11.010","article-title":"A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy","volume":"107","author":"Henricks","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib83","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","article-title":"Upfront genotyping of DPYD\u22172A to individualize fluoropyrimidine therapy: a safety and cost analysis","volume":"34","author":"Deenen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.11.028_bib84","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/s12885-022-09576-3","article-title":"Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients","volume":"22","author":"Tsiachristas","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib85","first-page":"203","article-title":"Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens","volume":"10","author":"Saam","year":"2011","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib86","first-page":"2039","article-title":"Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas","volume":"4","author":"Fety","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.11.028_bib87","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.11.028_bib88","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1634\/theoncologist.2011-0357","article-title":"Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6","volume":"17","author":"Kaldate","year":"2012","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2022.11.028_bib89","first-page":"381","article-title":"Prospective, multicenter study of 5-fluorouracil therapeutic drug monitoring in metastatic colorectal cancer treated in routine clinical practice","volume":"15","author":"Wilhelm","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib90","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2019.01.102","article-title":"Therapeutic drug monitoring as a tool to optimize 5-FU-based chemotherapy in gastrointestinal cancer patients older than 75 years","volume":"111","author":"Macaire","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib91","first-page":"3032","article-title":"Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-Fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients","volume":"6","author":"Bocci","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.11.028_bib92","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.clpt.2006.06.007","article-title":"A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity","volume":"80","author":"Bocci","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejca.2022.11.028_bib93","first-page":"219","article-title":"Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer","volume":"13","author":"Goldstein","year":"2014","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib94","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","article-title":"[Dihydropyrimidine d\u00e9hydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks]","volume":"105","author":"Loriot","year":"2018","journal-title":"Bull Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib95","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2020","author":"Cervantes","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.11.028_bib96","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"31","author":"Argil\u00e9s","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.11.028_bib97","unstructured":"Des recommandations pour pr\u00e9venir certaines toxicit\u00e9s s\u00e9v\u00e8res des chimioth\u00e9rapies par fluoropyrimidines. Haute Autorit\u00e9 de Sant\u00e9 n.d. https:\/\/www.has-sante.fr\/jcms\/c_2892234\/fr\/des-recommandations-pour-prevenir-certaines-toxicites-severes-des-chimiotherapies-par-fluoropyrimidines (accessed August 31, 2021)."},{"key":"10.1016\/j.ejca.2022.11.028_bib98","series-title":"EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine","year":"2020"},{"key":"10.1016\/j.ejca.2022.11.028_bib99","unstructured":"Reference ID: 4394864 - Accessdata.fda.gov."},{"key":"10.1016\/j.ejca.2022.11.028_bib100","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2174\/2212697X04666170817123425","article-title":"Upfront DPD deficiency detection to secure 5-fu administration: part 2- application to head-and-neck cancer patients","volume":"4","author":"Launay","year":"2017","journal-title":"Clin Cancer Drugs"},{"key":"10.1016\/j.ejca.2022.11.028_bib101","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/ijc.32022","article-title":"Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD\u22172A variant: a matched pair analysis","volume":"144","author":"Henricks","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib102","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00280-010-1282-4","article-title":"DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity","volume":"67","author":"Yang","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2022.11.028_bib103","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.11.028_bib104","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1001\/jama.2011.749","article-title":"Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis","volume":"305","author":"Biagi","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2022.11.028_bib105","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.ejca.2010.01.020","article-title":"Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis","volume":"46","author":"Des Guetz","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.11.028_bib106","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3390\/ph13110416","article-title":"Association of 5-FU therapeutic drug monitoring to DPD phenotype assessment may reduce 5-FU under-exposure","volume":"13","author":"Dolat","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ejca.2022.11.028_bib107","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.dld.2020.11.004","article-title":"When helping the minority of patients may hurt the majority: the case for DPD phenotyping and 5-fluorouracil therapeutic drug monitoring","volume":"53","author":"Tron","year":"2021","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ejca.2022.11.028_bib108","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s12885-020-06907-0","article-title":"DPD status and fluoropyrimidines-based treatment: high activity matters too","volume":"20","author":"Chamorey","year":"2020","journal-title":"BMC Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922017774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922017774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:39:20Z","timestamp":1760733560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922017774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":108,"alternative-id":["S0959804922017774"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.11.028","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}